{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T03:06:58Z","timestamp":1783998418748,"version":"3.55.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:00:00Z","timestamp":1783900800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T00:00:00Z","timestamp":1783987200000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004047","name":"Karolinska Institute","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004047","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Pancreatic ductal adenocarcinoma (PDAC) is characterized by profound therapy resistance, desmoplasia, and phenotypic plasticity. While sodium selenite is a redox-active compound with reported tumor-selective cytotoxicity, its impact on epithelial\u2013mesenchymal transition (EMT) states in PDAC remains insufficiently defined. We investigated whether selenite modulates EMT-associated phenotypes in a dose- and context-dependent manner using complementary in vitro and patient-derived ex vivo models and linked marker shifts to histological tumor regression in PDAC tissue slices.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Three PDAC cell lines spanning distinct baseline EMT states (PANC-1, HPAF-II, Capan-2) were profiled by quantitative immunofluorescence for a predefined epithelial (EpCAM, cytokeratin, E-cadherin) and mesenchymal-associated (AHNAK2, ITGAV, vimentin) protein panel, with or without TGF-\u03b2 pretreatment. Ex vivo tissue slices from treatment-na\u00efve, non-metastatic PDAC resections (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200910) were cultured in a within-patient paired design (0\u00a0h, 24\u00a0h, 48\u00a0h controls; 5 or 15 \u00b5M selenite during the second 24\u00a0h). Histological tumor regression was scored by a blinded pancreatic pathologist (Evans; CAP), compartment-resolved marker expression was quantified by multiplex immunofluorescence, and paired RNA sequencing was performed in a subset of donors (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20094).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In vitro, responses were phenotype-contingent: the epithelial-biased HPAF-II and Capan-2 lines showed partial epithelial reinforcement and a consistent reduction of mesenchymal markers (particularly ITGAV, vimentin), whereas the mesenchymal-biased PANC-1 exhibited limited modulation. TGF-\u03b2 pretreatment attenuated epithelial-promoting effects while suppression of mesenchymal markers was retained in a cell line\u2013dependent manner. In ex vivo slices, selenite induced a dose-dependent improvement in histological tumor regression and increased the tumor-compartment epithelial\u2013mesenchymal ratio at 15 \u00b5M, driven mainly by epithelial-marker upregulation, while mesenchymal markers showed no uniform suppression. At 15 \u00b5M, transcriptomics revealed a compact treatment response characterized by downregulation of basement-membrane\/ECM modules without broad reversal across EMT gene sets; EMT scoring indicated heterogeneous shifts at 5 \u00b5M and a more consistent epithelial-leaning shift at 15 \u00b5M in most donors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Selenite was associated with reinforcement of epithelial features mainly in malignant PDAC compartments in a baseline-state-, dose-, and context-dependent manner, with higher-dose phenotypic shifts occurring alongside stronger histological tumor response in clinically proximal models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>Not applicable.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13046-026-03778-4","type":"journal-article","created":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T14:45:25Z","timestamp":1783953925000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Selenite modulates phenotype-dependent epithelial\u2013mesenchymal plasticity in pancreatic ductal adenocarcinoma: integrated in vitro analyses and patient-derived ex vivo tissue-slice cultures"],"prefix":"10.1186","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0281-5428","authenticated-orcid":false,"given":"Ozan","family":"Aricak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-0918-5155","authenticated-orcid":false,"given":"Wenyang","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6863-5959","authenticated-orcid":false,"given":"Carlos Fern\u00e1ndez","family":"Moro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5396-6023","authenticated-orcid":false,"given":"Mehran","family":"Ghaderi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8588-6506","authenticated-orcid":false,"given":"Joakim","family":"Dillner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4576-9377","authenticated-orcid":false,"given":"Jonas","family":"Fuxe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2831-3837","authenticated-orcid":false,"given":"Mikael","family":"Bj\u00f6rnstedt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7373-8730","authenticated-orcid":false,"given":"T\u00edmea","family":"Szekercz\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,13]]},"reference":[{"key":"3778_CR1","doi-asserted-by":"publisher","first-page":"7055","DOI":"10.3390\/IJMS26157055","volume":"26","author":"S Peshin","year":"2025","unstructured":"Peshin S, Takrori E, Kodali NA, Bashir F, Singal S. Advances in the Management of Pancreatic Cancer: Current Strategies and Emerging Therapies. Int J Mol Sci. 2025;26:7055. https:\/\/doi.org\/10.3390\/IJMS26157055.","journal-title":"Int J Mol Sci"},{"key":"3778_CR2","doi-asserted-by":"publisher","first-page":"688377","DOI":"10.3389\/FONC.2021.688377","volume":"11","author":"DR Principe","year":"2021","unstructured":"Principe DR, Underwood PW, Korc M, Trevino JG, Munshi HG, Rana A. The Current Treatment Paradigm for Pancreatic Ductal Adenocarcinoma and Barriers to Therapeutic Efficacy. Front Oncol. 2021;11:688377. https:\/\/doi.org\/10.3389\/FONC.2021.688377.","journal-title":"Front Oncol"},{"key":"3778_CR3","doi-asserted-by":"publisher","first-page":"562","DOI":"10.3390\/diagnostics11030562","volume":"11","author":"J Ushio","year":"2021","unstructured":"Ushio J, Kanno A, Ikeda E, Ando K, Nagai H, Miwata T, Kawasaki Y, Tada Y, Yokoyama K, Numao N, Tamada K, Lefor AK, Yamamoto H. Pancreatic Ductal Adenocarcinoma: Epidemiology and Risk Factors. Diagnostics. 2021;11:562. https:\/\/doi.org\/10.3390\/diagnostics11030562.","journal-title":"Diagnostics"},{"key":"3778_CR4","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.pan.2014.10.001","volume":"15","author":"M Hidalgo","year":"2015","unstructured":"Hidalgo M, Cascinu S, Kleeff J, Labianca R, L\u00f6hr JM, Neoptolemos J, Real FX, Van Laethem JL, Heinemann V. Addressing the challenges of pancreatic cancer: Future directions for improving outcomes. Pancreatology. 2015;15:8\u201318. https:\/\/doi.org\/10.1016\/j.pan.2014.10.001.","journal-title":"Pancreatology"},{"key":"3778_CR5","doi-asserted-by":"publisher","first-page":"986","DOI":"10.3390\/cancers13050986","volume":"13","author":"NS Aboelella","year":"2021","unstructured":"Aboelella NS, Brandle C, Kim T, Ding ZC, Zhou G. Oxidative Stress in the Tumor Microenvironment and Its Relevance to Cancer Immunotherapy. Cancers (Basel). 2021;13:986. https:\/\/doi.org\/10.3390\/cancers13050986.","journal-title":"Cancers (Basel)"},{"key":"3778_CR6","doi-asserted-by":"publisher","first-page":"1156538","DOI":"10.3389\/fphar.2023.1156538","volume":"14","author":"Y Li","year":"2023","unstructured":"Li Y, Zhang X, Wang Z, Li B, Zhu H. Modulation of redox homeostasis: A strategy to overcome cancer drug resistance. Front Pharmacol. 2023;14:1156538. https:\/\/doi.org\/10.3389\/fphar.2023.1156538.","journal-title":"Front Pharmacol"},{"key":"3778_CR7","doi-asserted-by":"publisher","first-page":"3536","DOI":"10.3390\/nu7053536","volume":"7","author":"S Misra","year":"2015","unstructured":"Misra S, Boylan M, Selvam A, Spallholz JE, Bj\u00f6rnstedt M. Redox-Active Selenium Compounds\u2014From Toxicity and Cell Death to Cancer Treatment. Nutrients. 2015;7:3536\u201356. https:\/\/doi.org\/10.3390\/nu7053536.","journal-title":"Nutrients"},{"key":"3778_CR8","doi-asserted-by":"publisher","first-page":"100843","DOI":"10.1016\/j.tranon.2020.100843","volume":"13","author":"K Subburayan","year":"2020","unstructured":"Subburayan K, Thayyullathil F, Pallichankandy S, Cheratta AR, Galadari S. Superoxide-mediated ferroptosis in human cancer cells induced by sodium selenite. Transl Oncol. 2020;13:100843. https:\/\/doi.org\/10.1016\/j.tranon.2020.100843.","journal-title":"Transl Oncol"},{"key":"3778_CR9","doi-asserted-by":"publisher","first-page":"3169","DOI":"10.3390\/cancers13133169","volume":"13","author":"K Doello","year":"2021","unstructured":"Doello K, Mesas C, Qui\u00f1onero F, Perazzoli G, Cabeza L, Prados J, Melguizo C, Ortiz R. The antitumor activity of sodium selenite alone and in combination with gemcitabine in pancreatic cancer: An in vitro and in vivo study. Cancers (Basel). 2021;13:3169. https:\/\/doi.org\/10.3390\/cancers13133169.","journal-title":"Cancers (Basel)"},{"key":"3778_CR10","doi-asserted-by":"publisher","first-page":"965182","DOI":"10.3389\/fonc.2022.965182","volume":"12","author":"CF Moro","year":"2022","unstructured":"Moro CF, Selvam AK, Ghaderi M, Pimenoff VN, Gerling M, Boz\u00f3ky B, Elduayen SP, Dillner J, Bj\u00f6rnstedt M. Drug-induced tumor-specific cytotoxicity in a whole tissue ex vivo model of human pancreatic ductal adenocarcinoma. Front Oncol. 2022;12:965182. https:\/\/doi.org\/10.3389\/fonc.2022.965182.","journal-title":"Front Oncol"},{"key":"3778_CR11","doi-asserted-by":"publisher","first-page":"4978","DOI":"10.3390\/nu7064978","volume":"7","author":"O Brodin","year":"2015","unstructured":"Brodin O, Eksborg S, Wallenberg M, Asker-Hagelberg C, Larsen EH, Mohlkert D, Lenneby-Helleday C, Jacobsson H, Linder S, Misra S, Bj\u00f6rnstedt M. Pharmacokinetics and Toxicity of Sodium Selenite in the Treatment of Patients with Carcinoma in a Phase I Clinical Trial: The SECAR Study. Nutrients. 2015;7:4978\u201394. https:\/\/doi.org\/10.3390\/nu7064978.","journal-title":"Nutrients"},{"key":"3778_CR12","doi-asserted-by":"publisher","first-page":"295","DOI":"10.3390\/biomedicines11020295","volume":"11","author":"O Breuer","year":"2023","unstructured":"Breuer O, Brodin O, Razaghi A, Brodin D, Gammelgaard B, Bj\u00f6rnstedt M. Intravenous Infusion of High Dose Selenite in End-Stage Cancer Patients: Analysis of Systemic Exposure to Selenite and Seleno-Metabolites. Biomedicines. 2023;11:295. https:\/\/doi.org\/10.3390\/biomedicines11020295.","journal-title":"Biomedicines"},{"key":"3778_CR13","doi-asserted-by":"publisher","first-page":"17036","DOI":"10.1038\/sigtrans.2017.36","volume":"2","author":"J Jiang","year":"2017","unstructured":"Jiang J, Wang K, Chen Y, Chen H, Nice EC, Huang C. Redox regulation in tumor cell epithelial\u2013mesenchymal transition: Molecular basis and therapeutic strategy. Signal Transduct Target Ther. 2017;2:17036. https:\/\/doi.org\/10.1038\/sigtrans.2017.36.","journal-title":"Signal Transduct Target Ther"},{"key":"3778_CR14","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1186\/s12885-022-09965-8","volume":"22","author":"X Liu","year":"2022","unstructured":"Liu X, Jiang M, Pang C, Wang J, Hu L. Sodium selenite inhibits proliferation and metastasis through ROS-mediated NF\u2010\u03baB signaling in renal cell carcinoma. BMC Cancer. 2022;22:870. https:\/\/doi.org\/10.1186\/s12885-022-09965-8.","journal-title":"BMC Cancer"},{"key":"3778_CR15","doi-asserted-by":"publisher","first-page":"11400","DOI":"10.1073\/pnas.0902204106","volume":"106","author":"E Olm","year":"2009","unstructured":"Olm E, Fernandes AP, Hebert C, Rundl\u00f6f AK, Larsen EH, Danielsson O, Bj\u00f6rnstedt M. Extracellular thiol-assisted selenium uptake dependent on the xc\u2013 cystine transporter explains the cancer-specific cytotoxicity of selenite. Proc Natl Acad Sci U S A. 2009;106:11400\u20135. https:\/\/doi.org\/10.1073\/pnas.0902204106.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3778_CR16","doi-asserted-by":"publisher","first-page":"114730","DOI":"10.1016\/j.yexcr.2025.114730","volume":"452","author":"J Feng","year":"2025","unstructured":"Feng J, Yang M, Lin R, Shang K, Sun M, Guo Z, Wang Y, Zhou T, Yang F, Yang Y. NudCL2 suppresses pancreatic cancer progression by inhibiting SLC7A11-mediated EMT and metastasis. Exp Cell Res. 2025;452:114730. https:\/\/doi.org\/10.1016\/j.yexcr.2025.114730.","journal-title":"Exp Cell Res"},{"key":"3778_CR17","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1186\/s13045-022-01347-8","volume":"15","author":"Y Huang","year":"2022","unstructured":"Huang Y, Hong W, Wei X. The molecular mechanisms and therapeutic strategies of EMT in tumor progression and metastasis. J Hematol Oncol. 2022;15:129. https:\/\/doi.org\/10.1186\/s13045-022-01347-8.","journal-title":"J Hematol Oncol"},{"key":"3778_CR18","doi-asserted-by":"publisher","first-page":"740","DOI":"10.3390\/ph14080740","volume":"14","author":"J Dardare","year":"2021","unstructured":"Dardare J, Witz A, Merlin JL, Bochnakian A, Toussaint P, Gilson P, Harl\u00e9 A. Epithelial to Mesenchymal Transition in Patients with Pancreatic Ductal Adenocarcinoma: State-of-the-Art and Therapeutic Opportunities. Pharmaceuticals (Basel). 2021;14:740. https:\/\/doi.org\/10.3390\/ph14080740.","journal-title":"Pharmaceuticals (Basel)"},{"key":"3778_CR19","doi-asserted-by":"publisher","first-page":"2646148","DOI":"10.1155\/2017\/2646148","volume":"2017","author":"S Wang","year":"2017","unstructured":"Wang S, Huang S, Sun YL. Epithelial-Mesenchymal Transition in Pancreatic Cancer: A Review. Biomed Res Int. 2017;2017:2646148. https:\/\/doi.org\/10.1155\/2017\/2646148.","journal-title":"Biomed Res Int"},{"key":"3778_CR20","doi-asserted-by":"publisher","first-page":"1218855","DOI":"10.3389\/fonc.2023.1218855","volume":"13","author":"W Zhong","year":"2023","unstructured":"Zhong W, Sun T. Epithelial-mesenchymal transition (EMT) as a therapeutic target in cancer, II. Front Oncol. 2023;13:1218855. https:\/\/doi.org\/10.3389\/fonc.2023.1218855.","journal-title":"Front Oncol"},{"key":"3778_CR21","doi-asserted-by":"publisher","first-page":"e144","DOI":"10.1002\/mco2.144","volume":"3","author":"Z Huang","year":"2022","unstructured":"Huang Z, Zhang Z, Zhou C, Liu L, Huang C. Epithelial\u2013mesenchymal transition: The history, regulatory mechanism, and cancer therapeutic opportunities. MedComm (Beijing). 2022;3:e144. https:\/\/doi.org\/10.1002\/mco2.144.","journal-title":"MedComm (Beijing)"},{"key":"3778_CR22","doi-asserted-by":"publisher","first-page":"2934","DOI":"10.1038\/s41598-025-87337-5","volume":"15","author":"M Zardab","year":"2025","unstructured":"Zardab M, Chelala C, Saad A, Imrali A, Hughes C, Roberts R, Grose RP, Kocher HM. AHNAK2: a potential diagnostic biomarker for pancreatic cancer related to cellular motility. Sci Rep. 2025;15:2934. https:\/\/doi.org\/10.1038\/s41598-025-87337-5.","journal-title":"Sci Rep"},{"key":"3778_CR23","first-page":"22204","volume":"8","author":"Y Meng","year":"2015","unstructured":"Meng Y, Xu BQ, Fu ZG, Wu B, Xu B, Chen ZN, Li L. Cytoplasmic EpCAM over-expression is associated with favorable clinical outcomes in pancreatic cancer patients with Hepatitis B virus negative infection. Int J Clin Exp Med. 2015;8:22204\u201316.","journal-title":"Int J Clin Exp Med"},{"key":"3778_CR24","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/s41580-020-0237-9","volume":"21","author":"J Yang","year":"2020","unstructured":"Yang J, Antin P, Berx G, Blanpain C, Brabletz T, Bronner M, Campbell K, Cano A, Casanova J, Christofori G, Dedhar S, Derynck R, Ford HL, Fuxe J, Garc\u00eda de Herreros A, Goodall GJ, Hadjantonakis AK, Huang RJY, Kalcheim C, Kalluri R, Kang Y, Khew-Goodall Y, Levine H, Liu J, Longmore GD, Mani SA, Massagu\u00e9 J, Mayor R, McClay D, Mostov KE, Newgreen DF, Nieto MA, Puisieux A, Runyan R, Savagner P, Stanger B, Stemmler MP, Takahashi Y, Takeichi M, Theveneau E, Thiery JP, Thompson EW, Weinberg RA, Williams ED, Xing J, Zhou BP, Sheng G. Guidelines and definitions for research on epithelial\u2013mesenchymal transition. Nat Rev Mol Cell Biol. 2020;21:341\u201352. https:\/\/doi.org\/10.1038\/s41580-020-0237-9.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"3778_CR25","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.3390\/cells9041040","volume":"9","author":"M Sommariva","year":"2020","unstructured":"Sommariva M, Gagliano N. E-Cadherin in Pancreatic Ductal Adenocarcinoma: A Multifaceted Actor during EMT. Cells. 2020;9:1040. https:\/\/doi.org\/10.3390\/cells9041040.","journal-title":"Cells"},{"key":"3778_CR26","first-page":"559","volume":"140","author":"MH Sch\u00fcssler","year":"1992","unstructured":"Sch\u00fcssler MH, Skoudy A, Ramaekers F, Real FX. Intermediate filaments as differentiation markers of normal pancreas and pancreas cancer. Am J Pathol. 1992;140:559\u201368.","journal-title":"Am J Pathol"},{"key":"3778_CR27","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1038\/bjc.2011.93","volume":"104","author":"A Handra-Luca","year":"2011","unstructured":"Handra-Luca A, Hong SM, Walter K, Wolfgang C, Hruban R, Goggins M. Tumour epithelial vimentin expression and outcome of pancreatic ductal adenocarcinomas. Br J Cancer. 2011;104:1296\u2013302. https:\/\/doi.org\/10.1038\/bjc.2011.93.","journal-title":"Br J Cancer"},{"key":"3778_CR28","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1186\/s13046-021-01946-2","volume":"40","author":"M Kemper","year":"2021","unstructured":"Kemper M, Schiecke A, Maar H, Nikulin S, Poloznikov A, Galatenko V, Tachezy M, Gebauer F, Lange T, Riecken K, Tonevitsky A, Aigner A, Izbicki J, Schumacher U, Wicklein D. Integrin alpha-V is an important driver in pancreatic adenocarcinoma progression. J Exp Clin Cancer Res. 2021;40:260. https:\/\/doi.org\/10.1186\/s13046-021-01946-2.","journal-title":"J Exp Clin Cancer Res"},{"key":"3778_CR29","doi-asserted-by":"publisher","first-page":"108","DOI":"10.3389\/fgene.2018.00108","volume":"9","author":"H Klett","year":"2018","unstructured":"Klett H, Fuellgraf H, Levit-Zerdoun E, Hussung S, Kowar S, K\u00fcsters S, Bronsert P, Werner M, Wittel U, Fritsch R, Busch H, Boerries M. Identification and validation of a diagnostic and prognostic multi-gene biomarker panel for pancreatic ductal adenocarcinoma. Front Genet. 2018;9:108. https:\/\/doi.org\/10.3389\/fgene.2018.00108.","journal-title":"Front Genet"},{"key":"3778_CR30","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1038\/s41598-019-38603-w","volume":"9","author":"S Misra","year":"2019","unstructured":"Misra S, Moro CF, Chiaro M, Del, Pouso S, Sebesty\u00e9n A, L\u00f6hr M, Bj\u00f6rnstedt M, Verbeke CS. Ex vivo organotypic culture system of precision-cut slices of human pancreatic ductal adenocarcinoma. Sci Rep. 2019;9:2133. https:\/\/doi.org\/10.1038\/s41598-019-38603-w.","journal-title":"Sci Rep"},{"key":"3778_CR31","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1001\/archsurg.1992.01420110083017","volume":"127","author":"DB Evans","year":"1992","unstructured":"Evans DB, Rich TA, Byrd DR, Cleary KR, Connelly JH, Levin B, Charnsangavej C, Fenoglio CJ, Ames FC. Preoperative Chemoradiation and Pancreaticoduodenectomy for Adenocarcinoma of the Pancreas. Arch Surg. 1992;127:1335\u20139. https:\/\/doi.org\/10.1001\/archsurg.1992.01420110083017.","journal-title":"Arch Surg"},{"key":"3778_CR32","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1038\/s41379-020-00683-9","volume":"34","author":"BV Janssen","year":"2021","unstructured":"Janssen BV, Tutucu F, van Roessel S, Adsay V, Basturk O, Campbell F, Doglioni C, Esposito I, Feakins R, Fukushima N, Gill AJ, Hruban RH, Kaplan J, Koerkamp BG, Hong SM, Krasinskas A, Luchini C, Offerhaus J, Sarasqueta AF, Shi C, Singhi A, Stoop TF, Soer EC, Thompson E, van Tienhoven G, Velthuysen MLF, Wilmink JW, Besselink MG, Brosens LAA, Wang H, Verbeke CS, Verheij J. Amsterdam International Consensus Meeting: tumor response scoring in the pathology assessment of resected pancreatic cancer after neoadjuvant therapy. Mod Pathol. 2021;34:4\u201312. https:\/\/doi.org\/10.1038\/s41379-020-00683-9.","journal-title":"Mod Pathol"},{"key":"3778_CR33","doi-asserted-by":"publisher","first-page":"18278","DOI":"10.1038\/s41598-020-74067-z","volume":"10","author":"Y Matsuda","year":"2020","unstructured":"Matsuda Y, Ohkubo S, Nakano-Narusawa Y, Fukumura Y, Hirabayashi K, Yamaguchi H, Sahara Y, Kawanishi A, Takahashi S, Arai T, Kojima M, Mino-Kenudson M. Objective assessment of tumor regression in post-neoadjuvant therapy resections for pancreatic ductal adenocarcinoma: comparison of multiple tumor regression grading systems. Sci Rep. 2020;10:18278. https:\/\/doi.org\/10.1038\/s41598-020-74067-z.","journal-title":"Sci Rep"},{"key":"3778_CR34","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1093\/bjs\/znac350","volume":"110","author":"BV Janssen","year":"2022","unstructured":"Janssen BV, van Roessel S, van Dieren S, de Boer O, Adsay V, Basturk O, Brosens L, Campbell F, Chatterjee D, Chou A, Doglioni C, Esposito I, Feakins R, Fuchs TL, Fukushima N, Gill AJ, Hong SM, Hruban RH, Kaplan J, Krasinkas A, Luchini C, Shi C, Singhi A, Thompson E, Velthuysen MLF, Besselink MG, Verheij J, Wang H, Verbeke C, Fari\u00f1a A. Histopathological tumour response scoring in resected pancreatic cancer following neoadjuvant therapy: international interobserver study (ISGPP-1). Br J Surg. 2022;110:67\u201382. https:\/\/doi.org\/10.1093\/bjs\/znac350.","journal-title":"Br J Surg"},{"key":"3778_CR35","doi-asserted-by":"crossref","unstructured":"Bostick M, Bolduc N, Lehman A, Farmer A. Strand-Specific Transcriptome Sequencing Using SMART Technology. Curr Protoc Mol Biol. 2016;116:4.27.1-4.27.18.","DOI":"10.1002\/cpmb.22"},{"key":"3778_CR36","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1186\/1471-2164-12-507","volume":"12","author":"MA Kallio","year":"2011","unstructured":"Kallio MA, Tuimala JT, Hupponen T, Klemel\u00e4 P, Gentile M, Scheinin I, Koski M, K\u00e4ki J, Korpelainen EI. Chipster: user-friendly analysis software for microarray and other high-throughput data. BMC Genomics. 2011;12:507. https:\/\/doi.org\/10.1186\/1471-2164-12-507.","journal-title":"BMC Genomics"},{"key":"3778_CR37","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1093\/bioinformatics\/btu170","volume":"30","author":"AM Bolger","year":"2014","unstructured":"Bolger AM, Lohse M, Usadel B. Trimmomatic: a flexible trimmer for Illumina sequence data. Bioinformatics. 2014;30:2114\u201320. https:\/\/doi.org\/10.1093\/bioinformatics\/btu170.","journal-title":"Bioinformatics"},{"key":"3778_CR38","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","volume":"29","author":"A Dobin","year":"2013","unstructured":"Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, Batut P, Chaisson M, Gingeras TR. STAR: ultrafast universal RNA-seq aligner. Bioinformatics. 2013;29:15\u201321. https:\/\/doi.org\/10.1093\/bioinformatics\/bts635.","journal-title":"Bioinformatics"},{"key":"3778_CR39","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/s41416-020-01178-9","volume":"124","author":"SV Vasaikar","year":"2021","unstructured":"Vasaikar SV, Deshmukh AP, den Hollander P, Addanki S, Kuburich NA, Kudaravalli S, Joseph R, Chang JT, Soundararajan R, Mani SA. EMTome: a resource for pan-cancer analysis of epithelial-mesenchymal transition genes and signatures. Br J Cancer. 2021;124:259\u201369. https:\/\/doi.org\/10.1038\/s41416-020-01178-9.","journal-title":"Br J Cancer"},{"key":"3778_CR40","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","volume":"1","author":"A Liberzon","year":"2015","unstructured":"Liberzon A, Birger C, Thorvaldsd\u00f3ttir H, Ghandi M, Mesirov JP, Tamayo P. The Molecular Signatures Database (MSigDB) hallmark gene set collection. Cell Syst. 2015;1:417\u201325. https:\/\/doi.org\/10.1016\/j.cels.2015.12.004.","journal-title":"Cell Syst"},{"key":"3778_CR41","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.devcel.2018.05.027","volume":"45","author":"NM Aiello","year":"2018","unstructured":"Aiello NM, Maddipati R, Norgard RJ, Balli D, Li J, Yuan S, Yamazoe T, Black T, Sahmoud A, Furth EE, Bar-Sagi D, Stanger BZ. EMT subtype influences epithelial plasticity and mode of cell migration. Dev Cell. 2018;45:681\u2013e954. https:\/\/doi.org\/10.1016\/j.devcel.2018.05.027.","journal-title":"Dev Cell"},{"key":"3778_CR42","doi-asserted-by":"publisher","first-page":"e1005911","DOI":"10.1371\/journal.pcbi.1005911","volume":"14","author":"S Koplev","year":"2018","unstructured":"Koplev S, Lin K, Dohlman AB, Ma\u2019ayan A. Integration of pan-cancer transcriptomics with RPPA proteomics reveals mechanisms of epithelial-mesenchymal transition. PLoS Comput Biol. 2018;14:e1005911. https:\/\/doi.org\/10.1371\/journal.pcbi.1005911.","journal-title":"PLoS Comput Biol"},{"key":"3778_CR43","doi-asserted-by":"publisher","first-page":"220","DOI":"10.3389\/fbioe.2020.00220","volume":"8","author":"P Chakraborty","year":"2020","unstructured":"Chakraborty P, George JT, Tripathi S, Levine H, Jolly MK. Comparative Study of Transcriptomics-Based Scoring Metrics for the Epithelial-Hybrid-Mesenchymal Spectrum. Front Bioeng Biotechnol. 2020;8:220. https:\/\/doi.org\/10.3389\/fbioe.2020.00220.","journal-title":"Front Bioeng Biotechnol"},{"key":"3778_CR44","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/nprot.2008.211","volume":"4","author":"DW Huang","year":"2009","unstructured":"Huang DW, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009;4:44\u201357. https:\/\/doi.org\/10.1038\/nprot.2008.211.","journal-title":"Nat Protoc"},{"key":"3778_CR45","doi-asserted-by":"publisher","first-page":"W216","DOI":"10.1093\/nar\/gkac194","volume":"50","author":"BT Sherman","year":"2022","unstructured":"Sherman BT, Hao M, Qiu J, Jiao X, Baseler MW, Lane HC, Imamichi T, Chang W. DAVID: a web server for functional enrichment analysis and functional annotation of gene lists (2021 update). Nucleic Acids Res. 2022;50:W216\u201321. https:\/\/doi.org\/10.1093\/nar\/gkac194.","journal-title":"Nucleic Acids Res"},{"key":"3778_CR46","doi-asserted-by":"publisher","first-page":"686","DOI":"10.3390\/cancers16040686","volume":"16","author":"LM Philipp","year":"2024","unstructured":"Philipp LM, Yesilyurt UU, Surrow A, K\u00fcnstner A, Mehdorn AS, Hauser C, Gundlach JP, Will O, Hoffmann P, Stahmer L, Franzenburg S, Knaack H, Schumacher U, Busch H, Sebens S. Epithelial and Mesenchymal-like Pancreatic Cancer Cells Exhibit Different Stem Cell Phenotypes Associated with Different Metastatic Propensities. Cancers (Basel). 2024;16:686. https:\/\/doi.org\/10.3390\/cancers16040686.","journal-title":"Cancers (Basel)"},{"key":"3778_CR47","doi-asserted-by":"publisher","first-page":"eaau8544","DOI":"10.1126\/scisignal.aau8544","volume":"12","author":"Y Katsuno","year":"2019","unstructured":"Katsuno Y, Meyer DS, Zhang Z, Shokat KM, Akhurst RJ, Miyazono K, Derynck R. Chronic TGF-\u03b2 exposure drives stabilized EMT, tumor stemness, and cancer drug resistance with vulnerability to bitopic mTOR inhibition. Sci Signal. 2019;12:eaau8544. https:\/\/doi.org\/10.1126\/scisignal.aau8544.","journal-title":"Sci Signal"},{"key":"3778_CR48","doi-asserted-by":"publisher","first-page":"5981","DOI":"10.21873\/anticanres.11186","volume":"36","author":"X Dai","year":"2016","unstructured":"Dai X, Thongchot S, Dokduang H, Loilome W, Khuntikeo N, Titapun A, Ungarreevittaya P, Yongvanit P, Techasen A, Namwat N. Potential of selenium compounds as new anticancer agents for cholangiocarcinoma. Anticancer Res. 2016;36:5981\u20138. https:\/\/doi.org\/10.21873\/anticanres.11186.","journal-title":"Anticancer Res"},{"key":"3778_CR49","doi-asserted-by":"publisher","first-page":"e191945","DOI":"10.1172\/JCI191945","volume":"135","author":"V Pantazopoulou","year":"2025","unstructured":"Pantazopoulou V, Kubota CS, Ogawa S, Gulay KCM, Lin X, Song H, Weitz JR, Tiriac H, Lowy AM, Engle DD. Experimental models of pancreas cancer: what has been the impact for precision medicine? J Clin Invest. 2025;135:e191945. https:\/\/doi.org\/10.1172\/JCI191945.","journal-title":"J Clin Invest"},{"key":"3778_CR50","doi-asserted-by":"publisher","first-page":"14614","DOI":"10.1038\/s41598-020-65911-3","volume":"10","author":"M Ghaderi","year":"2020","unstructured":"Ghaderi M, Fern\u00e1ndez Moro C, Pouso Elduayen S, Hultin E, Verbeke CS, Bj\u00f6rnstedt M, Dillner J. Genome-wide transcriptome profiling of ex-vivo precision-cut slices from human pancreatic ductal adenocarcinoma. Sci Rep. 2020;10:14614. https:\/\/doi.org\/10.1038\/s41598-020-65911-3.","journal-title":"Sci Rep"},{"key":"3778_CR51","doi-asserted-by":"publisher","first-page":"3549","DOI":"10.1007\/s00204-019-02611-6","volume":"93","author":"E Bigaeva","year":"2019","unstructured":"Bigaeva E, Gore E, Simon E, Zwick M, Oldenburger A, de Jong KP, Hofker HS, Schlep\u00fctz M, Nicklin P, Boersema M, Rippmann JF, Olinga P. Transcriptomic characterization of culture-associated changes in murine and human precision-cut tissue slices. Arch Toxicol. 2019;93:3549\u201383. https:\/\/doi.org\/10.1007\/s00204-019-02611-6.","journal-title":"Arch Toxicol"},{"key":"3778_CR52","doi-asserted-by":"publisher","first-page":"4385","DOI":"10.3390\/IJMS14034385","volume":"14","author":"P Chen","year":"2013","unstructured":"Chen P, Wang RR, Ma XJ, Liu Q, Ni JZ. Different Forms of Selenoprotein M Differentially Affect A\u03b2 Aggregation and ROS Generation. Int J Mol Sci. 2013;14:4385\u201399. https:\/\/doi.org\/10.3390\/IJMS14034385.","journal-title":"Int J Mol Sci"}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13046-026-03778-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-026-03778-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-026-03778-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T03:02:53Z","timestamp":1783998173000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13046-026-03778-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,13]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3778"],"URL":"https:\/\/doi.org\/10.1186\/s13046-026-03778-4","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,13]]},"assertion":[{"value":"31 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Swedish Ethical Review Authority (Etikpr\u00f6vningsmyndigheten; decision numbers: 2012\/1657-31\/4, 2019\u221200788, 2020\u201306587, 2022-02855-02-277976, 2024-04486-02). All patients provided written informed consent. Samples were pseudonymized prior to researcher access and the study complied with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable. The manuscript does not contain identifiable individual-level data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"160"}}